- Home
- VRDN vs AUPH Comparison
VRDN vs AUPH Comparison
Compare VRDN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- AUPH
- Stock Information
- Founded
- VRDN 2006
- AUPH 1993
- Country
- VRDN United States
- AUPH Canada
- Employees
- VRDN N/A
- AUPH N/A
- Industry
- VRDN Medical Specialities
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- AUPH Health Care
- Exchange
- VRDN Nasdaq
- AUPH Nasdaq
- Market Cap
- VRDN 1.3B
- AUPH 1.1B
- IPO Year
- VRDN N/A
- AUPH 1999
- Fundamental
- Price
- VRDN $15.67
- AUPH $7.59
- Analyst Decision
- VRDN Strong Buy
- AUPH Strong Buy
- Analyst Count
- VRDN 11
- AUPH 2
- Target Price
- VRDN $38.50
- AUPH $11.50
- AVG Volume (30 Days)
- VRDN 728.3K
- AUPH 1.6M
- Earning Date
- VRDN 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- VRDN N/A
- AUPH N/A
- EPS Growth
- VRDN N/A
- AUPH N/A
- EPS
- VRDN N/A
- AUPH 0.27
- Revenue
- VRDN $302,000.00
- AUPH $247,295,000.00
- Revenue This Year
- VRDN N/A
- AUPH $12.15
- Revenue Next Year
- VRDN $17,102.33
- AUPH $18.31
- P/E Ratio
- VRDN N/A
- AUPH $28.53
- Revenue Growth
- VRDN 4.86
- AUPH 29.20
- 52 Week Low
- VRDN $9.90
- AUPH $5.20
- 52 Week High
- VRDN $27.20
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- VRDN 61.91
- AUPH 40.36
- Support Level
- VRDN $13.84
- AUPH $7.29
- Resistance Level
- VRDN $14.85
- AUPH $8.86
- Average True Range (ATR)
- VRDN 0.82
- AUPH 0.34
- MACD
- VRDN -0.03
- AUPH -0.06
- Stochastic Oscillator
- VRDN 82.81
- AUPH 19.37
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.